Derma misses 'one shot' at drug development

Derma Sciences Inc. (NASDAQ:DSCI) fell $1.56 (28%) to $4.04 on Thursday on news it will terminate development of aclerastide ( DSC127), the only candidate in the company's drug development portfolio.

Derma said that after an interim futility analysis for efficacy, a data monitoring committee recommended halting enrollment in Phase III trials of aclerastide to treat diabetic foot ulcers. By YE15, the company will end the ongoing studies of the compound and halt its preclinical development in scar reduction and radiation dermatitis. ...